Some medicines that have been withdrawn from the market over the past 50 years including DES
See the list of medicines that have been withdrawn from the market over the past 50 years including Diethylstilbestrol DES! Too bad the decision to stop prescribing or even prescribe these medicines in the first place came too late …!
Homeopathy enjoys edge over allopathy in many ways. As it is an acknowledged fact that those using allopathic medicines for a long time contract several other diseases. Homeopathy, however, has no such side-effects.
There are many differences in both the disciplines of medicines. Let’s just focus on one main difference and that is the fact that none of the homeopathic medicines introduced during the last two hundred and fifty years was withdrawn from the market.
The more a homeopathic medicine is used the more useful it becomes. Its finer details are brought out with the passage of time and the homeopathic physicians use it with even greater confidence and precision.
In contrast there is a long list of allopathic medicines withdrawn, discarded or banned after they were initially introduced with very high claims. These all medicines were introduced by the “medical science” after great “medical research”! Well! what sort of science it is that changes its stance after every six months?! You may call it business or you may call it the commercialization of consumer products but of course not science.
A few allopathic medicines discarded, and reasons for their withdrawal during the last 50 years are as follows:
Thalidomide (1950s-1960s): withdrawn because of risk of disturbance to the growth and development of embryo or fetus.
Lysergic Acid Diethylamide commonly known as LSD(1950s-1960s) marketed as a psychiatric drug: because it widely caused drug addiction.
Diethylstilbestrol (1970s): because of risk of disturbance to the growth and development of embryo or fetus.
Phenformin and Buformin (1978): because of risk of lactic acidosis; Ticrynafen (1982): because of risk of liver damage.
Zimelidine (1983): because of risk of Guillain-Barré syndrome (an acute neurological disorder followed by progressive muscular dystrophy).
Phenacetin (1983) an ingredient in “A.P.C.” tablet: risk of cancer and kidney disease.
Methaqualone (1984): because of risk of addiction and overdose.Nomefensine (Merital) (1986): Because of risk of hemolytic anemia.
Triazolam (1991): withdrawn in the United Kingdom because of risk of psychiatric adverse drug reactions.
Temafloxacin (1992): withdrawn in the United States because of allergic reactions and cases of hemolytic anemia, leading to three patients’ deaths.
Flosequinan (1993): withdrawn in the United States because of an increased risk of hospitalization or death.
Alpidem (1996): because of serious liver damage.
Chlormezanone (1996): because of serious cases of toxic epidermal necrolysis.
Temazepam (1999): withdrawn in Sweden and Norway because of diversion, abuse, and a relatively high rate of overdose deaths.
The details regarding thousands of other discarded, banned or withdrawn medicines can be checked on the Internet. The reason behind this frequent withdrawal of medicines is that these are introduced not to serve humanity but to earn more and more. Medicines production and marketing have become a big business worldwide. Pharmaceutical companies fund research in medicines because of their own monetary considerations.
Homeopathic medicines, however, are not given directly to the patients. They are first tested on healthy human volunteers before being given to the patients. They work along with the body’s own defense mechanism. Homeopathy treats the whole person and not just the part as mind and body influence each other and imbalance in one system causes imbalance in the other. Besides, homeopathic medicines are highly diluted substances and without any side-effects.
A system of medicine which is unable to stand the test of time is not worthy of being called medical science.
Dr Asghar Ali Shah, practicing homeopathic physician Thursday, November 15, 2012
Covering DiEthylStilbestrol worldwide drug disaster
Over the past few days, there has been an unprecedented flurry of media attention on DES related health issues. This come after a long-awaited DES study was published on October 06th in the New England Journal of Medicine (MEJM) which carefully documents elevated risk for women exposed to diethylstilbestrol (DES in short) for a host of medical problems including cancer, infertility, ectopic pregnancies, preterm labour, …. As yet, there has been no coverage from the UK press despite a call on UK journalists to make this information available to the public.
DES prescribed to women in the 1940s, 1950s, and 1960s to prevent miscarriages, had serious, untoward effects in daughters of these women, including the development of a rare type of cancer of the uterus. There has been renewed interest in light of a recent report in the New England Journal of Medicine documenting lifelong health complications facing daughters of women given DES.
Reproductive tissues are not the only targets of DES. The immune system is also known to be a target for estrogens. Dr. S. Ansar Ahmed, professor of immunology at Virginia Tech, led a National Institutes of Health study in the 1990s on how exposure to DES in utero affects the immune system later in life using a mouse model.
A drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study finds.
A drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new U.S. federal study finds.
A woman given the anti-miscarriage drug diethylstilbestrol supports a call for a government-backed education campaign to highlight the dangers of exposure to the medication
In a follow-up to the DES drug disaster, researchers (including one of the authors of the original reports in the early 1970s) have examined reproductive health in a large cohort of women exposed to DES in utero. Their results were published last week in the New England Journal of Medicine, and they show that the health effects apparently continue beyond the reproductive years
The DES breast cancer lawsuit, together with a bombshell New England Journal of Medicine article published yesterday — which suggests that infertility is twice as common and that breast cancer risk is nearly doubled in “DES daughters” — has ushered in a new awareness of the drug after decades when its lingering effects went under the radar.
A large study of the daughters of women who had been given DES, the first synthetic form of estrogen, during pregnancy has found that exposure to the drug while in the womb (in utero) is associated with many reproductive problems and an increased risk of certain cancers and pre-cancerous conditions.
Beginning in 1940, diethylstilbestrol, known as DES, was used clinically to prevent certain complications of pregnancy. In the 1950s, clinical studies showed DES was ineffective for this purpose. In the late 1960s, an unusual occurrence of a rare …
Back in the 1940s, ’50s and ’60s, doctors prescribed a hormone called diethylstilbestrol, or DES, to millions of pregnant women in the unfounded belief it could prevent miscarriages. Smack in the middle of this period, the deformed thalidomide babies …
Diethylstilbestrol was prescribed in the mistaken belief it could reduce pregnancy complications, but the daughters of the women who took it are still living with its effects …
Women who were exposed in utero to diethylstilbestrol have a higher lifetime risk for several adverse health outcomes, according to a study published in the Oct. 6 issue of the New England Journal of Medicine. …
In-utero exposure to diethylstilbestrol was associated with a high lifetime risk of a broad spectrum of adverse outcomes in a follow-up study of patients now in their 40s, 50s, and 60s, according to a report in the Oct. 6 issue of the New England …
Explain that the teratogenic effects of diethylstilbestrol have continued to exact a heavy toll throughout the lifetime of women who were exposed to the drug in utero. Point out that DES-exposed women …
The daughters of women given diethylstilbestrol (DES), a drug commonly used decades ago to prevent miscarriages and birth defects, are showing high rates of breast cancer and infertility problems, according to recent research. …
Millions of women alive today were exposed to a chemical called DES – diethylstilbestrol – in their mother’s uterus. The chemical, an early synthetic estrogen, was administered to some pregnant women before 1971 to help reduce risk of miscarriages and …
Washington, Sept 06 (ANI): Daughters of women who took a synthetic estrogen called diethylstilbestrol (DES) while pregnant decades ago are now facing a greater chance of being infertile and developing cancer, according to a large study by the National …
The study in Thursday’s New England Journal of Medicine examines the daughters of females exposed in the womb to diethylstilbestrol (DES), which was prescribed in the mistaken belief it could reduce certain complications of pregnancy. …
by macleans.ca on Thursday, October 6, 2011 12:56pm – 0 Comments DES (or diethylstilbestrol), an anti-miscarriage drug widely used between 1940 and 1970, has been linked to health problems—including breast cancer, infertility, difficult pregnancies and …
DES or diethylstilbestrol have been prescribed to pregnant women for the belief that it will reduce complications during pregnancy. The National Cancer Institute researchers and scientists have been following about 6500 women including those exposed to …
Women whose mothers were given the drug diethylstilbestrol (DES) during pregnancy are at increased risk for fertility problems and cancer as they age, new research shows. This study from the US National Cancer …
A study published by the New England Journal of Medicine on Thursday found daughters of women who took diethylstilbestrol (DES) while pregnant face a greater chance of being infertile and developing a rare vaginal cancer. …
A study appearing in Thursday’s New England Journal of Medicine examines women exposed in the womb to diethylstilbestrol (DES), which was prescribed in the mistaken belief it could reduce certain complications of pregnancy. Researchers at the National …
A comprehensive study looking at the drug diethylstilbestrol (DES) that was widely used by pregnant women in Europe and the United States to prevent problems in pregnancy such as miscarriage and premature birth from the 1940s until the 1960s suggests …
The Associated Press reports that the drug, an artificial form of estrogen called DES (diethylstilbestrol), was often prescribed to pregnant women in pill or cream form between 1940 and 1960. When it was discovered that the teenage daughters of women …
That drug was DES, or diethylstilbestrol, which was widely prescribed in the US beginning in 1940 to help stave off miscarriage — until 1971, when the US Food and Drug Administration decided that the drug doesn’t work and that it causes cancer. …
Diethylstilbestrol, or DES, widely was used in the United States, Europe and elsewhere from the 1940s through the 1960s to prevent miscarriage, premature birth, bleeding and other problems. Many companies made it as pills and creams. …
DES, or diethylstilbestrol, was widely used in the United States, Europe and elsewhere from the 1940s through the 1960s to prevent miscarriage, premature birth, bleeding and other problems. Many companies made and sold it as pills, creams and other …
Daughters of women who took a synthetic estrogen called diethylstilbestrol (DES) while pregnant decades ago are now facing a greater chance of being infertile and developing cancer, according to a large study by the National Cancer Institute in the …
Risks for other health problems vary. DES, or diethylstilbestrol, was widely used in the United States, Europe and elsewhere from the 1940s through the 1960s to prevent miscarriage, premature birth, bleeding and other problems.
AP A drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer and other health problems that are showing up now, a new federal study …
Millions of women in the 1940s, 50s, and 60s who wanted to make sure they had safe pregnancies, took a drug called DES. The women likely didn`t know it then, but that drug came with side effects that are surfacing 50 plus years later in their children. …
Millions of women exposed to the first synthetic form of estrogen are at risk of cancer . A National Institutes of Health study followed daughters of pregnant women given synthetic estrogen called DES from the 1940’s to the 1970s. … Drugs women took years ago may affect daughters WNDU-TV
A drug millions of pregnant women took decades ago may increase health risks among their daughters. An estimated four million Americans were exposed to DES, a synthetic estrogen prescribed to prevent miscarriages and pregnancy complications, …
A new federal study finds that a drug that millions of pregnant women took decades ago to prevent miscarriage and complications has put their daughters at higher risk for breast cancer. Cancer and other health problems are showing …
by Art Writ, October 6th, 2011 Decades ago, women have taken a certain drug that lessens the risk of miscarriage. However, just recently, researchers have found out that the complications and side effects of this drug has placed their daughters at …
Les femmes exposées dans le ventre de leur mère au Distilbène, premier œstrogène de synthèse utilisé dès 1940, souffrent de nombreux problèmes de reproduction et sont soumises à un net accroissement du risque de certains cancers, selon une vaste étude …
Une étude menée par les chercheurs de l’Institut National du Cancer américain publiée aujourd’hui dans le New England Journal of Medecine révèle de nouveaux effets négatifs liés à l’exposition intra-utérine au distilbène. En cause : des risques accrus …
Une étude menée par des chercheurs de l’Institut national américain du cancer (NCI) montre que des femmes exposées au stade fœtal au Distilbène, un œstrogène de synthèse, souffrent aujourd’hui de problèmes de reproduction et sont davantage sujettes à …
Les résultats d’une vaste étude publiée aujourd’hui dans le New England of Medicine révèlent que les femmes exposées au Distilbène dans le ventre de leur mère sont soumises à un risque accru de cancer. Entre 1948 et 1976, 200 000 femmes ont été …
Reproductive tissues are not the only targets of DES. The immune system is also known to be a target for estrogens. Dr. S. Ansar Ahmed, professor of immunology at Virginia Tech, led a National Institutes of Health study in the 1990s on how exposure to DES in utero affects the immune system later in life using a mouse model.
See the list of medicines that have been withdrawn from the market over the past 50 years including Diethylstilbestrol DES! Too bad the decision to stop prescribing or even prescribe these medicines in the first place came too late …!
Over the past few days, there has been an unprecedented flurry of media attention on DES related health issues. This come after a long-awaited DES study was published on October 06th in the New England Journal of Medicine (MEJM) which carefully documents elevated risk for women exposed to diethylstilbestrol (DES in short) for a host of medical problems including cancer, infertility, ectopic pregnancies, preterm labour, …. As yet, there has been no coverage from the